Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial

Zbigniew Zylicz, Malgorzata Krajnik, Adriaan Alistar van Sorge, Massimo Costantini

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Severe pruritus may be an idiopathic phenomenon or associated with advanced systemic disease. It is one of the most distressing and difficult to treat symptoms. Uncontrolled studies have suggested that, in patients experiencing severe pruritus, paroxetine appeared to have a rapid anti-pruritic effect. This study was a prospective double-blind, randomized within patient comparison of paroxetine and placebo. The intensity of pruritus was measured subjectively with a numerical analogue scale. The primary endpoint of the trial was the mean pruritus score, measured for seven days after randomization and after cross-over. The secondary endpoint was individual global response to the treatment. Response was defined as at least 50% reduction of intensity of pruritus in the last three days of the treatment period vs. baseline. Adverse effects and patient satisfaction and preferences were also recorded. Twenty-six patients were included in the study; 17 of them had solid tumors, 4 had hematological malignancies and 5 had various nonmalignant or idiopathic conditions. Eight patients had drug-induced pruritus (none opioid-induced), 7 patients had paraneoplastic pruritus and 3 had cholestatic pruritus. After a run-in period, patients were randomly assigned to treatment with 20 mg paroxetine or placebo. The crossover took place after 7 days. Two patients discontinued treatment because of adverse effects of paroxetine. Twenty-four patients treated with paroxetine had lower pruritus intensity scores over the 7 treatment periods (mean±SE=5.2±0.32) as compared to placebo (mean±SE=6.0±0.32). Mean difference between placebo and paroxetine was 0.78 (95% CI=0.37-1.19). Nine of twenty-four patients (37.5%) fulfilled criteria of response. The onset of anti-pruritic action was observed usually after 2-3 days, irrespective of the order of treatment. The outcome of this study indicates that paroxetine is effective in the treatment of severe pruritus of non-dermatological origin.

Original languageEnglish
Pages (from-to)1105-1112
Number of pages8
JournalJournal of Pain and Symptom Management
Volume26
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Paroxetine
Pruritus
Randomized Controlled Trials
Placebos
Therapeutics
Patient Preference
Hematologic Neoplasms
Random Allocation
Patient Satisfaction
Opioid Analgesics
Outcome Assessment (Health Care)

Keywords

  • Chemotherapy
  • Induced itch
  • Itch
  • Paraneoplastic phenomenon
  • Paroxetine
  • Pruritus

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Paroxetine in the treatment of severe non-dermatological pruritus : A randomized, controlled trial. / Zylicz, Zbigniew; Krajnik, Malgorzata; Sorge, Adriaan Alistar van; Costantini, Massimo.

In: Journal of Pain and Symptom Management, Vol. 26, No. 6, 12.2003, p. 1105-1112.

Research output: Contribution to journalArticle

Zylicz, Zbigniew ; Krajnik, Malgorzata ; Sorge, Adriaan Alistar van ; Costantini, Massimo. / Paroxetine in the treatment of severe non-dermatological pruritus : A randomized, controlled trial. In: Journal of Pain and Symptom Management. 2003 ; Vol. 26, No. 6. pp. 1105-1112.
@article{b3929f6f6d4c4fda9d2d898f79152a7e,
title = "Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial",
abstract = "Severe pruritus may be an idiopathic phenomenon or associated with advanced systemic disease. It is one of the most distressing and difficult to treat symptoms. Uncontrolled studies have suggested that, in patients experiencing severe pruritus, paroxetine appeared to have a rapid anti-pruritic effect. This study was a prospective double-blind, randomized within patient comparison of paroxetine and placebo. The intensity of pruritus was measured subjectively with a numerical analogue scale. The primary endpoint of the trial was the mean pruritus score, measured for seven days after randomization and after cross-over. The secondary endpoint was individual global response to the treatment. Response was defined as at least 50{\%} reduction of intensity of pruritus in the last three days of the treatment period vs. baseline. Adverse effects and patient satisfaction and preferences were also recorded. Twenty-six patients were included in the study; 17 of them had solid tumors, 4 had hematological malignancies and 5 had various nonmalignant or idiopathic conditions. Eight patients had drug-induced pruritus (none opioid-induced), 7 patients had paraneoplastic pruritus and 3 had cholestatic pruritus. After a run-in period, patients were randomly assigned to treatment with 20 mg paroxetine or placebo. The crossover took place after 7 days. Two patients discontinued treatment because of adverse effects of paroxetine. Twenty-four patients treated with paroxetine had lower pruritus intensity scores over the 7 treatment periods (mean±SE=5.2±0.32) as compared to placebo (mean±SE=6.0±0.32). Mean difference between placebo and paroxetine was 0.78 (95{\%} CI=0.37-1.19). Nine of twenty-four patients (37.5{\%}) fulfilled criteria of response. The onset of anti-pruritic action was observed usually after 2-3 days, irrespective of the order of treatment. The outcome of this study indicates that paroxetine is effective in the treatment of severe pruritus of non-dermatological origin.",
keywords = "Chemotherapy, Induced itch, Itch, Paraneoplastic phenomenon, Paroxetine, Pruritus",
author = "Zbigniew Zylicz and Malgorzata Krajnik and Sorge, {Adriaan Alistar van} and Massimo Costantini",
year = "2003",
month = "12",
doi = "10.1016/j.jpainsymman.2003.05.004",
language = "English",
volume = "26",
pages = "1105--1112",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Paroxetine in the treatment of severe non-dermatological pruritus

T2 - A randomized, controlled trial

AU - Zylicz, Zbigniew

AU - Krajnik, Malgorzata

AU - Sorge, Adriaan Alistar van

AU - Costantini, Massimo

PY - 2003/12

Y1 - 2003/12

N2 - Severe pruritus may be an idiopathic phenomenon or associated with advanced systemic disease. It is one of the most distressing and difficult to treat symptoms. Uncontrolled studies have suggested that, in patients experiencing severe pruritus, paroxetine appeared to have a rapid anti-pruritic effect. This study was a prospective double-blind, randomized within patient comparison of paroxetine and placebo. The intensity of pruritus was measured subjectively with a numerical analogue scale. The primary endpoint of the trial was the mean pruritus score, measured for seven days after randomization and after cross-over. The secondary endpoint was individual global response to the treatment. Response was defined as at least 50% reduction of intensity of pruritus in the last three days of the treatment period vs. baseline. Adverse effects and patient satisfaction and preferences were also recorded. Twenty-six patients were included in the study; 17 of them had solid tumors, 4 had hematological malignancies and 5 had various nonmalignant or idiopathic conditions. Eight patients had drug-induced pruritus (none opioid-induced), 7 patients had paraneoplastic pruritus and 3 had cholestatic pruritus. After a run-in period, patients were randomly assigned to treatment with 20 mg paroxetine or placebo. The crossover took place after 7 days. Two patients discontinued treatment because of adverse effects of paroxetine. Twenty-four patients treated with paroxetine had lower pruritus intensity scores over the 7 treatment periods (mean±SE=5.2±0.32) as compared to placebo (mean±SE=6.0±0.32). Mean difference between placebo and paroxetine was 0.78 (95% CI=0.37-1.19). Nine of twenty-four patients (37.5%) fulfilled criteria of response. The onset of anti-pruritic action was observed usually after 2-3 days, irrespective of the order of treatment. The outcome of this study indicates that paroxetine is effective in the treatment of severe pruritus of non-dermatological origin.

AB - Severe pruritus may be an idiopathic phenomenon or associated with advanced systemic disease. It is one of the most distressing and difficult to treat symptoms. Uncontrolled studies have suggested that, in patients experiencing severe pruritus, paroxetine appeared to have a rapid anti-pruritic effect. This study was a prospective double-blind, randomized within patient comparison of paroxetine and placebo. The intensity of pruritus was measured subjectively with a numerical analogue scale. The primary endpoint of the trial was the mean pruritus score, measured for seven days after randomization and after cross-over. The secondary endpoint was individual global response to the treatment. Response was defined as at least 50% reduction of intensity of pruritus in the last three days of the treatment period vs. baseline. Adverse effects and patient satisfaction and preferences were also recorded. Twenty-six patients were included in the study; 17 of them had solid tumors, 4 had hematological malignancies and 5 had various nonmalignant or idiopathic conditions. Eight patients had drug-induced pruritus (none opioid-induced), 7 patients had paraneoplastic pruritus and 3 had cholestatic pruritus. After a run-in period, patients were randomly assigned to treatment with 20 mg paroxetine or placebo. The crossover took place after 7 days. Two patients discontinued treatment because of adverse effects of paroxetine. Twenty-four patients treated with paroxetine had lower pruritus intensity scores over the 7 treatment periods (mean±SE=5.2±0.32) as compared to placebo (mean±SE=6.0±0.32). Mean difference between placebo and paroxetine was 0.78 (95% CI=0.37-1.19). Nine of twenty-four patients (37.5%) fulfilled criteria of response. The onset of anti-pruritic action was observed usually after 2-3 days, irrespective of the order of treatment. The outcome of this study indicates that paroxetine is effective in the treatment of severe pruritus of non-dermatological origin.

KW - Chemotherapy

KW - Induced itch

KW - Itch

KW - Paraneoplastic phenomenon

KW - Paroxetine

KW - Pruritus

UR - http://www.scopus.com/inward/record.url?scp=0345275977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345275977&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2003.05.004

DO - 10.1016/j.jpainsymman.2003.05.004

M3 - Article

C2 - 14654262

AN - SCOPUS:0345275977

VL - 26

SP - 1105

EP - 1112

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 6

ER -